how many people use glp 1 drugs GLP-1 Agonists Weight Loss Market Report, 2025-2030 Products - Data Briefs -
Description
Study results: what did they find
DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006
Limited head-to-head studies compare established glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dipeptidyl peptidase-4 inhibitors (DPP-4is), and sodium-glucose co-transporter-2 inhibitors (SGLT-2is) to insulin in the management of uncontrolled type 2 diabetes mellitus (T2DM)
Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide
But theres a tradeoff
78.64.4 l/min/gkw, sodium excretion 7.40.8 vs
